B. Metzler Seel. Sohn & Co. Ag Neurocrine Biosciences Inc Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 4,799 shares of NBIX stock, worth $602,322. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,799
Previous 2,519
90.51%
Holding current value
$602,322
Previous $346,000
59.54%
% of portfolio
0.01%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding NBIX
# of Institutions
629Shares Held
94.2MCall Options Held
692KPut Options Held
406K-
Black Rock Inc. New York, NY14.2MShares$1.78 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.25 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$646 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$323 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.9MShares$238 Million4.37% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...